Frequency and Clinical Presentation of Mucocutaneous Disease Due to Mycoplasma pneumoniae Infection in Children With Community-Acquired Pneumonia by Meyer Sauteur, Patrick M et al.








Frequency and Clinical Presentation of Mucocutaneous Disease Due to
Mycoplasma pneumoniae Infection in Children With Community-Acquired
Pneumonia
Meyer Sauteur, Patrick M ; Theiler, Martin ; Buettcher, Michael ; Seiler, Michelle ; Weibel, Lisa ;
Berger, Christoph
Abstract: Importance The diagnosis of Mycoplasma pneumoniae infection as the cause of mucocuta-
neous disease is challenging because current diagnostic tests are not able to differentiate M pneumoniae
infection from carriage. Objective To examine the frequency and clinical presentation of M pneumoniae-
induced mucocutaneous disease in children with community-acquired pneumonia (CAP) using improved
diagnostics. Design, Setting, and Participants This prospective, longitudinal cohort study included 152
children aged 3 to 18 years with CAP enrolled in a CAP study from May 1, 2016, to April 30, 2017,
at the University Children’s Hospital Zurich. Children were inpatients or outpatients with clinically
defined CAP according to the British Thoracic Society guidelines. Data analysis was performed from
July 10, 2017, to June 29, 2018. Main Outcomes and Measures Frequency and clinical presentation of
M pneumoniae-induced mucocutaneous disease in childhood CAP. Mycoplasma pneumoniae infection
was diagnosed by polymerase chain reaction (PCR) of oropharyngeal samples and confirmed with the
measurement of specific peripheral blood IgM antibody-secreting cells by enzyme-linked immunospot as-
say to differentiate M pneumoniae-infected patients from carriers with CAP caused by other pathogens.
Mucocutaneous disease was defined as any eruptive lesion that involved skin and/or mucous membranes
occurring during the CAP episode. Results Among 152 enrolled children with CAP (median [interquartile
range] age, 5.7 [4.3-8.9] years; 84 [55.3%] male), 44 (28.9%) tested positive for M pneumoniae by PCR;
of these, 10 children (22.7%) developed mucocutaneous lesions. All 10 patients with mucocutaneous
eruptions tested positive for specific IgM antibody-secreting cells. Skin manifestations were found in 3
cases (2.8%) of M pneumoniae PCR-negative CAP (P < .001). The spectrum of M pneumoniae-induced
mucocutaneous disease included M pneumoniae-induced rash and mucositis (3 cases [6.8%]), urticaria (2
cases [4.5%]), and maculopapular skin eruptions (5 cases [11.4%]). Two patients had ocular involvement
as the sole mucosal manifestation (bilateral anterior uveitis and nonpurulent conjunctivitis). Patients
with M pneumoniae-induced mucocutaneous disease had longer duration of prodromal fever (median
[interquartile range], 10.5 [8.3-11.8] vs 7.0 [5.5-9.5] days; P = .02) and higher C-reactive protein levels
(median [interquartile range], 31 [22-59] vs 16 [7-23] mg/L; P = .04) than patients with CAP due to
M pneumoniae without mucocutaneous manifestations. They were also more likely to require oxygen
(5 [50%] vs 1 [5%]; P = .007), to require hospitalization (7 [70%] vs 4 [19%]; P = .01), and to develop
long-term sequelae (3 [30%] vs 0; P = .03). Conclusions and Relevance Mucocutaneous disease occurred
significantly more frequently in children with CAP due to M pneumoniae than in children with CAP
of other origins. Mycoplasma pneumoniae-induced mucocutaneous disease was associated with increased
systemic inflammation, morbidity, and a higher risk of long-term sequelae.
DOI: https://doi.org/10.1001/jamadermatol.2019.3602
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LisaWeibel, MD; Christoph Berger, MD
IMPORTANCE The diagnosis ofMycoplasma pneumoniae infection as the cause of
mucocutaneous disease is challenging because current diagnostic tests are not able to
differentiateMpneumoniae infection from carriage.
OBJECTIVE To examine the frequency and clinical presentation ofMpneumoniae–induced
mucocutaneous disease in children with community-acquired pneumonia (CAP) using
improved diagnostics.
DESIGN, SETTING, AND PARTICIPANTS This prospective, longitudinal cohort study included 152
children aged 3 to 18 years with CAP enrolled in a CAP study fromMay 1, 2016, to April 30,
2017, at the University Children’s Hospital Zurich. Children were inpatients or outpatients with
clinically defined CAP according to the British Thoracic Society guidelines. Data analysis was
performed from July 10, 2017, to June 29, 2018.
MAIN OUTCOMES ANDMEASURES Frequency and clinical presentation ofMpneumoniae–
inducedmucocutaneous disease in childhood CAP.Mycoplasma pneumoniae infection was
diagnosed by polymerase chain reaction (PCR) of oropharyngeal samples and confirmed with
themeasurement of specific peripheral blood IgM antibody-secreting cells by enzyme-linked
immunospot assay to differentiateMpneumoniae–infected patients from carriers with CAP
caused by other pathogens. Mucocutaneous disease was defined as any eruptive lesion that
involved skin and/or mucous membranes occurring during the CAP episode.
RESULTS Among 152 enrolled children with CAP (median [interquartile range] age, 5.7
[4.3–8.9] years; 84 [55.3%]male), 44 (28.9%) tested positive forMpneumoniae by PCR;
of these, 10 children (22.7%) developedmucocutaneous lesions. All 10 patients with
mucocutaneous eruptions tested positive for specific IgM antibody–secreting cells.
Skin manifestations were found in 3 cases (2.8%) ofMpneumoniae PCR-negative CAP
(P < .001). The spectrum ofMpneumoniae–inducedmucocutaneous disease included
Mpneumoniae–induced rash andmucositis (3 cases [6.8%]), urticaria (2 cases [4.5%]), and
maculopapular skin eruptions (5 cases [11.4%]). Two patients had ocular involvement as the
sole mucosal manifestation (bilateral anterior uveitis and nonpurulent conjunctivitis).
Patients withMpneumoniae–inducedmucocutaneous disease had longer duration of
prodromal fever (median [interquartile range], 10.5 [8.3-11.8] vs 7.0 [5.5-9.5] days; P = .02)
and higher C-reactive protein levels (median [interquartile range], 31 [22-59] vs 16 [7-23]
mg/L; P = .04) than patients with CAP due toMpneumoniaewithout mucocutaneous
manifestations. They were also more likely to require oxygen (5 [50%] vs 1 [5%]; P = .007),
to require hospitalization (7 [70%] vs 4 [19%]; P = .01), and to develop long-term sequelae
(3 [30%] vs 0; P = .03).
CONCLUSIONS AND RELEVANCEMucocutaneous disease occurred significantlymore
frequently in children with CAP due toMpneumoniae than in children with CAP of other
origins.Mycoplasma pneumoniae–inducedmucocutaneous disease was associated with
increased systemic inflammation, morbidity, and a higher risk of long-term sequelae.
JAMA Dermatol. doi:10.1001/jamadermatol.2019.3602
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includemaculopapular skin eruptions, urticaria, andmucocu-
taneouseruptionsalongthespectrumoferythemamultiforme,
Stevens-Johnson syndrome, and toxic epidermal necrolysis.2
MucocutaneouseruptionsduetoMpneumoniae frequentlypre-
sentwithprominentmucositis andminimalor evenabsent cu-
taneousinvolvement,referredtoasMpneumoniae–inducedrash
and mucositis (MIRM).3 Diagnosis ofM pneumoniae infection
in such cases has mainly been based on serologic testing and
rarelyonpolymerase chain reaction (PCR)ofupper respiratory
tract specimens.2-4 However, PCR and serologic testing for
M pneumoniae are not able to reliably differentiate infected
patients from carriers with CAP caused by other pathogens.5,6
Mpneumoniae carriage in the upper respiratory tract has been
reported inupto56%ofhealthychildren.5-7Thus, thedetection
ofMpneumoniaewith thesecurrentlyavailablediagnostic tests
may cause an overestimation of the M pneumoniae–induced
mucocutaneous disease burden.
A recentprospective, longitudinalCAPstudy6 amongchil-
dren found that themeasurement of specific peripheral blood
IgMantibody–secretingcells (ASCs)byanenzyme-linkedimmu-
nospot (ELISpot) assay improved diagnosis ofM pneumoniae
infection.6Usingthisdataset,weaimedtoassess the frequency
and clinical presentation ofMpneumoniae–inducedmucocu-
taneous disease in childhood CAP.
Methods
Patients
This cohort study included patients enrolled between May 1,
2016, and April 30, 2017, at University Children’s Hospital
Zurich.Theprimary inclusioncriterionwasCAPdefinedaccord-
ing to the British Thoracic Society guidelines8 in previously
healthychildrenaged3to18years.6Mucocutaneousdiseasewas
definedasanyeruptive lesionthat involvedskinand/ormucous
membranes occurring during the CAP episode;MIRMwas de-




sent was obtained from all parents and from children 14 years
or older. All datawere deidentified.
Study Procedures
Eligible patients with CAP were tested for the presence
of M pneumoniae DNA in oropharyngeal swab samples by
M pneumoniae–specific PCR.9 Patients with mucocutaneous
disease who had positive PCR results were tested with
the M pneumoniae–specific IgM ASC ELISpot assay to con-
firm M pneumoniae infection, as described previously.6
All children had a thorough clinical examination of the
skin and mucous membranes. Patients with confirmed
M pneumoniae–induced mucocutaneous disease were
followed up for 6 months.
Statistical Analysis
Categorical and continuous variables were compared with
the Fisher exact test and Mann-Whitney test, respectively. A
case-control analysis was performed between patients with
CAP and mucocutaneous disease who tested positive on the
M pneumoniae–specific IgM ASC ELISpot assay and those
without mucocutaneous manifestations. A 2-tailed P < .05
was considered to be statistically significant. Analyses were
performed with R software, version 3.6.0 (R Foundation for
Statistical Computing).
Results
Among 152 enrolled childrenwithCAP (median [interquartile
range] age, 5.7 [4.3–8.9] years; 84 [55.3%] male), 44 (28.9%)
tested positive for M pneumoniae by PCR; of these, 10 chil-
dren (22.7%) (median age, 8.7 years; range, 3.8-14.6 years; 6
[60%] male) developed mucocutaneous lesions (eFigure 1 in
the Supplement). Diagnosis of M pneumoniae infection was
confirmed in all 10 patients with mucocutaneous involve-
ment bydetection ofMpneumoniae–specific IgMASCs. In the
108 patientswith CAPwho tested negative forMpneumoniae
by PCR, mucocutaneous disease (maculopapular skin erup-
tions and conjunctivitis) was observed in 3 (2.8%) (P < .001
comparedwithpatientswithCAPwho testedpositivebyPCR).
Of the 44 patients with CAPwho had positiveMpneumo-
niae PCR results, 34 had peripheral blood mononuclear cells
available for M pneumoniae–specific IgM ASC ELISpot assay
testing and 31 tested positive. A case-control analysis of these
31patientswithCAPwithpositiveMpneumoniae–specific IgM
ASCELISpot assay results found that the 10patientswithmu-
cocutaneous disease had longer duration of prodromal fever
(median, 10.5 days; interquartile range, 8.3-11.8 days;P = .02)
and higher C-reactive protein levels (median, 31 mg/L; inter-
quartile range, 22-59mg/L [to convert to nanomoles per liter,
multiply by 9.524]; P = .04) and were more likely to require
oxygen (odds ratio, 17.6; 95% CI, 1.5-984.1; P = .007) com-
pared with 21 patients without mucocutaneous manifesta-
tions (Table1).Patientswithmucocutaneousdiseaseweremore
Key Points
Question What are the frequency and clinical characteristics
ofMycoplasma pneumoniae–inducedmucocutaneous disease
in children with community-acquired pneumonia (CAP)?
Findings In this cohort study of 152 children with CAP,
mucocutaneous eruptions developed in 10 of 44 patients (22.7%)
with CAP due toMpneumoniae and 3 of 108 patients (2.8%) with
CAP of other causes, a significant difference. Among patients with
Mpneumoniae infection, mucocutaneous disease was significantly
associated with longer duration of fever, higher C-reactive protein
level, and greater likelihood of hospitalization, oxygen use,
and sequelae.
Meaning The findings suggest that mucocutaneous disease is
a frequent manifestation ofMpneumoniae infection in children
and is associated with increased systemic inflammation, morbidity,
and a higher risk of long-term sequelae.
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likely to be hospitalized (odds ratio, 9.0; 95% CI, 1.4-81.4;
P = .01) and to develop long-term sequelae (3 [30%] vs 0;
P = .03), including bronchiolitis obliterans, exertional dysp-
nea, and postinflammatory pigmentary alterations.
Among the 10 patients withMpneumoniae–inducedmu-
cocutaneous disease, 3 (6.8%) were diagnosed with MIRM,
2 (4.5%)withurticaria, and5 (11.4%)withmaculopapular skin
eruptions (Figure and eFigures 2-4 in the Supplement). De-
tailed clinical characteristics of patients withMpneumoniae–
induced mucocutaneous disease are given in Table 2. All
patientswithMIRMwerehospitalized (median,7.0days; range,
5.0-13.0 days) and received antibiotics againstMpneumoniae
and a short course of systemic corticosteroids (methylpred-
nisolone, 1-3mg/kg, daily for 3 days).Mucocutaneous lesions









(n = 21) OR (95% CI) P Value
Age, median (IQR), y 8.7 (6.0-12.2) 8.6 (6.7-11.0) NA .85
Male 6 (60) 11 (52) 1.4 (0.2-8.6) >.99
Season at enrollment
Spring (March-May) 3 (30) 3 (15) 2.5 (0.3-23.5) .36
Summer (June-August) 3 (30) 7 (33) 0.9 (0.1-5.5) >.99
Autumn (September-November) 2 (20) 7 (33) 0.5 (0.0-3.7) .68
Winter (December-February) 2 (20) 4 (19) 1.1 (0.1-9.4) >.99
Prior antibiotic treatment 7 (70) 9 (43) 4.4 (0.6-53.8) .12
Preexisting disease 0 (0) 1 (5) NA >.99
Asthma or history of wheezing 0 (0) 1 (5) NA >.99
Pulmonary characteristics
Prodrome, median (IQR), d
Respiratory symptoms 10.5 (8.3-11.8) 9.0 (6.0-10.0) NA .17




39.3 (38.7-39.9) 39.0 (39.0-39.5) NA .60
Runny nose 2 (20) 5 (24) 0.8 (0.1-6.4) >.99
Sore throat 3 (30) 2 (10) 3.9 (0.4-55.6) .30
Cough 10 (100) 19 (90) NA >.99
Chest pain 0 (0) 3 (14) NA .53
Wheezing 0 (0) 0 (0) NA >.99
Oxygen saturation <93% 5 (50) 1 (5) 17.6 (1.5-984.1) .007
Oxygen supply,
median (IQR), d
4.0 (2.0-6.0) 3.0 NA .60
Dermatologic characteristics
Prodrome, median (IQR), d 2.0 (1.5-2.0) NA NA NA
Cutaneous involvement 9 (90) NA NA NA
Mucosal involvement 5 (50) NA NA NA
Oral 3 NA NA NA
Ocular 5 NA NA NA
Urogenital 2 NA NA NA
Anal 1 NA NA NA
Laboratory characteristics,
median (IQR)
WBC count, /μL 8800 (7000-10 800) 10 600 (7100-12 900) NA .60
Neutrophil count, /μL 6100 (4300-8700) 7800 (3800-10 400) NA .70
CRP level, mg/L 31 (22-59) 16 (7-23) NA .04
Treatment
Antibiotics 8 (80) 20 (95) 0.2 (0.0-4.6) .24
Corticosteroids 5 (50) 0 (0) NA .001
Clinical outcomes
Hospitalization 7 (70) 4 (19) 9.0 (1.4-81.4) .01
LOS, median (IQR), d 7.0 (4.5-9.0) 3.5 (2.5-4.0) NA .07
ICU admission 0 (0) 0 (0) NA NA
Long-term sequelae 3 (30) 0 (0) NA .03
Respiratory sequelae 2 NA NA NA
Dermatologic sequelae 1 NA NA NA
Abbreviations:
CAP, community-acquired
pneumonia; CRP, C-reactive protein;
ICU, intensive care unit;
IQR, interquartile range;
LOS, length of hospital stay;
NA, not applicable; OR, odds ratio;
WBC, white blood cell.
SI conversion factors: to convert
CRP values to nanomoles per liter,
multiply by 9.524; to convert
neutrophil andWBC counts to
×109/L, multiply by 0.001.
a Data are presented as number
(percentage) of study participants
unless otherwise indicated.
Differences between groups were
determined by theMann-Whitney




mucocutaneous disease were not
included in the publication about
the original cohort6 because of
incomplete specimens at inclusion.
c Inclusion criteria for CAPwere
presence of temperature higher
than 38.5 °C and tachypnea,
according to the British Thoracic
Society guidelines.8
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healed without scarring, and postinflammatory pigmentary
alterations were observed in 1 patient (eFigure 5 in the
Supplement). No recurrenceswere observed during 6-month
follow-up.
Discussion
To our knowledge, this is the first prospective longitudinal
cohort study to examine M pneumoniae–induced mucocuta-
neous disease in children. We found that M pneumoniae–
induced mucocutaneous disease occurred in 1 of 4 children
with CAP who tested positive for M pneumoniae by PCR,
including a considerable proportion (6.8%) with MIRM.
Mycoplasma pneumoniae infection was confirmed in all pa-
tients with mucocutaneous involvement by the detection of
specific IgM ASCs, which allows, in contrast to PCR and IgM
serologic testing, the differentiation of M pneumoniae infec-
tion from carriage.6
Our study’s observed frequency of M pneumoniae–
inducedmucocutaneousdisease (22.7%) is in agreementwith
the estimates in the literature (25.0%-33.0%),2-4 but MIRM
occurred in our studymore frequently (6.8% vs 1.0%-5.0%).2
Although M pneumoniae may infrequently cause extensive
blistering skindisease that is clinically indistinguishable from
Stevens-Johnson syndrome and toxic epidermal necrolysis,2
our data support the concept of MIRM as a specific entity.3
A new proposed revised classification for severe cutaneous
reactions in children suggests the term reactive infectious
mucocutaneous eruption10 to capture other pathogens that
can also trigger a MIRM-like clinical presentation, such as
Chlamydophila pneumoniae.11 These case definitions are
critical for patient management because early recognition of
mucocutaneous disease as infection triggered rather than
drug triggered (Stevens-Johnson syndrome and toxic epider-
mal necrolysis) enables more specific treatment and progno-
sis information and, most importantly, avoids restriction of
possibly causative drugs.
The observation that M pneumoniae–induced mucocu-
taneous disease was associated with more pronounced
inflammation is in agreement with a recent study about
M pneumoniae–associated Stevens-Johnson syndrome12 and
suggests a distinct immune reaction. The rare detection of
M pneumoniae from mucocutaneous lesions3,4,13 further
suggests an immune-mediated pathogenesis. Proposed
immune mechanisms include immune complex–mediated
vascular injury, cytotoxic T cell–mediated epithelial injury,
or antibody-mediated disease.2-4,14
No evidence-based treatment guidelines exist for
Mpneumoniae–inducedmucocutaneousdisease. It remainsun-
clearwhetherantibioticsandanti-inflammatorytreatment,such
as systemic corticosteroids or intravenous immunoglobulins,
haveanyindicationgiventheoverall favorablediseasecourse.3,15
Nevertheless, patients require closemonitoring todetect early
signs suggestive of potential complications, such as bron-
chiolitis obliterans ormucosal sequelae.2,3,12
Figure.Mycoplasma pneumoniae–Induced Rash andMucositis
Purulent conjunctivitis A Oral mucositis B
Genital mucositisC Anal mucositis D
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Table 2. Clinical Characteristics ofMycoplasma pneumoniae–InducedMucocutaneous Disease
Characteristic
Case No.
1 2 3 4 5 6 7 8 9 10


















NA Amoxicillin (1) Amoxicillin (10) Amoxicillin (5)
Pulmonary characteristics
Prodrome: fever and RTI, d 10 11 8 9 14 8 11 7 12 13
Symptoms and signs
Runny nose No No No No No Yes Yes No No No
Sore throat Yes No Yes No No Yes No No No No
Cough Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Oxygen saturation <93% No No Yes No No Yes Yes No Yes Yes
Oxygen supply, d NA NA 2 NA NA 10 2 NA 6 4
Pulmonary infiltrate
on chest radiograph
Yes Yes Yes Yes Yes Yes Yes NA Yes Yes
Dermatologic characteristics
Prodrome, d 2 4 2 (–6)a 0 (–5)a 2 2 2 0
Cutaneous involvement Yes No Yes Yes Yes Yes Yes Yes Yes Yes
Acral Yes NA No No No No No Yes No No
Generalized No NA No Yes Yes Yes Yes No Yes No
Truncal No NA Yes No No No No No No Yes
Morphologic characteristics
Vesiculobullous No NA No No No No No No No No
Targetoid Yes NA Yes No No No No No No No
Papules No NA No No No No Yes Yes No Yes
Macules No NA No No No Yes Yes Yes Yes Yes
Urticarial No NA No Yes Yes No No No No No
Mucosal involvement Yes Yes Yes No Yes No No Yes No No










NA NA Bilateral anterior
uveitisb
NA NA






NA None NA NA None NA NA































































































































































































































Table 2. Clinical Characteristics ofMycoplasma pneumoniae–InducedMucocutaneous Disease (continued)
Characteristic
Case No.
1 2 3 4 5 6 7 8 9 10
Laboratory characteristics
WBC count, /μL 16 100 62 000 10 800 6600 8600 8800 6900 11 700 9100 8700
Neutrophil count, /μL 13 280 3800 8700 5250 7390 6100 3860 9020 4280 5300
CRP level, mg/L 13 173 63 26 <4 46 36 72 24 21
Treatment (duration, d)



















Prednisolone (3) NA NAd NA NA
Clinical outcome
Hospitalization Yes Yes Yes No No Yes Yes No Yes Yes
LOS, d 5 7 13 NA NA 11 2 NA 7 4
Reason Severe mucositis Severe mucositis Severe mucositis,
oxygen supply
NA NA Oxygen supply Oxygen supply NA Oxygen supply Oxygen supply
ICU admission No No No NA NA No No NA No No
Long-term sequelae No Yes Yes No No Yes No No No No
Respiratory sequelae NA Exertional
dyspnea
None NA NA Bronchiolitis
obliterans
NA NA NA NA
Dermatologic sequelae NA None Postinflammatory
pigmentary
alteration




17 7 NA 4 34 7 4 22 2 4
Abbreviations: CRP, C-reactive protein; ICU, intensive care unit; LOS, length of hospital stay; MIRM,Mycoplasma
pneumoniae–induced rash andmucositis; NA, not applicable; RTI, respiratory tract infection; WBC, white
blood cell.
SI conversion factors: to convert CRP values to nanomoles per liter, multiply by 9.524; to convert neutrophils
andWBCs to ×109/L, multiply by 0.001.
a Days after enrollment.
bAnterior uveitis presented with bilateral conjunctival injection and eye pain for 2 days. An ophthalmologic
examination revealed cells and flare in the anterior chamber. Apart from testing forMpneumoniae, a diagnostic
workup was negative for antinuclear antibodies, rheumatoid factor, total immunoglobulins, and parvovirus B19.
c Already treated with an antibiotic againstMpneumoniae before admission.
dTreatment consisted of topical corticosteroids in addition to a 1-week course of doxycycline. The uveitis resolved








































































































































































































































induced eruptions. However, the precisemicrobiological diag-
nosis ofMpneumoniae infection togetherwith the short period
ofdrugexposureandthenonpruritic, faintpresentationoferup-
tions inmost of these cases favors an infectious cause.
Conclusions
In this study, mucocutaneous disease occurred significantly
more frequently in children with CAP due to M pneumoniae
than in children with CAP of other origins. Mycoplasma
pneumoniae–induced mucocutaneous disease was associ-
ated with increased systemic inflammation, morbidity, and
a higher risk of long-term sequelae. The overall prognosis of
M pneumoniae–induced mucocutaneous disease was good.
Further investigations are required to elucidate microbial or
host characteristics that lead to this relevant and potentially
severe extrapulmonary manifestation of M pneumoniae
infection.
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